A Dying Breed

Redistribution of federal financial backing may have drastic implications for cancer studies, they warn With federal research funds increasingly being earmarked for such publicly visible areas of biomedical investigation as AIDS and women's health, cancer research institutions in the United States are finding themselves in a bind. Saddled with a shrinking piece of the budgetary pie, heads of the nation's basic cancer research cente

Written bySteven Benowitz
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Saddled with a shrinking piece of the budgetary pie, heads of the nation's basic cancer research centers are struggling to maintain their high scientific standards while making ends meet. They worry that the frustration of stagnant funding levels will drive their best researchers to seek greener pastures. And they are concerned that, in the long run, the necessity of cutting costs will serve only to hinder scientific progress.

The Wistar Institute of Anatomy and Biology in Philadelphia shares the woes of other basic science cancer centers: how to deal with an uncertain funding environment, given the increased push by federal funding agencies to support applied research.

Compounding matters, Wistar has had the added burden of a three-year legal battle over management issues with former director Hilary Koprowski, settled in June 1993. Although just three years ago Wistar faced a $2 million budget deficit and declining morale, today the staff credits ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies